Proteasome inhibitors MG-132 and bortezomib induce AKR1C1, AKR1C3, AKR1B1, and AKR1B10 in human colon cancer cell lines SW-480 and HT-29

Chemico-Biological Interactions

Volumn 191, Issue 1-3, 2011, Pages 239-249

  Ebert, Bettina ^a   Kisiela, Michael ^a   Wsól, Vladimir ^b   Maser, Edmund ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b Charles University in Prague Faculty of Pharmacy   (Czech Republic)

Author keywords

Aldo keto reductase; Colon cells; Proteasome inhibitors

Indexed keywords

ALDO KETO REDUCTASE 1B1; ALDO KETO REDUCTASE 1B10; ALDO KETO REDUCTASE 1C1; ALDO KETO REDUCTASE 1C2; ALDO KETO REDUCTASE 1C3; ALDO KETO REDUCTASE 1C4; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BETA ACTIN; BORTEZOMIB; CYCLOOXYGENASE 2; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 2; PS 431; STEROID REDUCTASE; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG;

CANCER CELL CULTURE; CELL STRAIN; CELL STRAIN HT 29; CELL STRAIN SW 480; CELLULAR DISTRIBUTION; COLON CANCER; CONCENTRATION RESPONSE; CONFERENCE PAPER; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME ASSAY; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; UPREGULATION;

20-HYDROXYSTEROID DEHYDROGENASES; 3-HYDROXYSTEROID DEHYDROGENASES; ALCOHOL OXIDOREDUCTASES; ALDEHYDE REDUCTASE; BORONIC ACIDS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ENZYME INDUCTION; GENE EXPRESSION REGULATION, NEOPLASTIC; HT29 CELLS; HUMANS; HYDROXYPROSTAGLANDIN DEHYDROGENASES; LEUPEPTINS; MALEATES; NF-E2-RELATED FACTOR 2; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; RNA, MESSENGER; THIOCYANATES; TIME FACTORS;

EID: 79957569340     PISSN: 00092797     EISSN: 18727786     Source Type: Journal    
DOI: 10.1016/j.cbi.2010.12.026     Document Type: Conference Paper

References (47)

1. T.M. Penning, M.E. Burczynski, J.M. Jez, C.F. Hung, H.K. Lin, H. Ma, M. Moore, N. Palackal, K. Ratnam, Human 3alpha-hydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the aldo-keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones, Biochem. J. 351 (Pt 1) (2000) 67-77.
2. S. Steckelbroeck, Y. Jin, S. Gopishetty, B. Oyesanmi, T.M. Penning, Human cytosolic 3alpha-hydroxysteroid dehydrogenases of the aldo-keto reductase superfamily display significant 3beta-hydroxysteroid dehydrogenase activity: implications for steroid hormone metabolism and action, J. Biol. Chem. 279 (11) (2004) 10784-10795.
3. Y. Jin, T.M. Penning, Aldo-keto reductases and bioactivation/ detoxication, Annu. Rev. Pharmacol. Toxicol. 47 (2007) 263-292.
4. M. Plebuch, M. Soldan, C. Hungerer, L. Koch, E. Maser, Increased resistance of tumor cells to daunorubicin after transfection of cDNAs coding for anthracycline inactivating enzymes, Cancer Lett. 255 (1) (2007) 49-56. (Pubitemid 47212606)
5. A. Atalla, U. Breyer-Pfaff, E. Maser, Purification and characterization of oxidoreductases-catalyzing carbonyl reduction of the tobacco-specific nitrosamine 4-methylnitrosamino-1-(3-pyridyl)-1-butanone (NNK) in human liver cytosol, Xenobiotica 30 (8) (2000) 755-769.
6. T.M. Penning, M.E. Burczynski, C.F. Hung, K.D. McCoull, N.T. Palackal, L.S. Tsuruda, Dihydrodiol dehydrogenases and polycyclic aromatic hydrocarbon activation: generation of reactive and redox active o-quinones, Chem. Res. Toxicol. 12 (1) (1999) 1-18. (Pubitemid 29048827)
7. T. Smuc, N. Hevir, M. Ribic-Pucelj, B. Husen, H. Thole, T.L. Rizner, Disturbed estrogen and progesterone action in ovarian endometriosis, Mol. Cell. Endocrinol. 301 (1-2) (2009) 59-64.
8. J. Birtwistle, R.E. Hayden, F.L. Khanim, R.M. Green, C. Pearce, N.J. Davies, N. Wake, H. Schrewe, J.P. Ride, J.K. Chipman, C.M. Bunce, The aldo-keto reductase AKR1C3 contributes to 7,12-dimethylbenz(a)anthracene-3,4-dihydrodiol mediated oxidative DNA damage in myeloid cells: implications for leukemogenesis, Mutat. Res. 662 (1-2) (2009) 67-74.
9. N.T. Palackal, S.H. Lee, R.G. Harvey, I.A. Blair, T.M. Penning, Activation of polycyclic aromatic hydrocarbon trans-dihydrodiol proximate carcinogens by human aldo-keto reductase (AKR1C) enzymes and their functional overexpression in human lung carcinoma (A549) cells, J. Biol. Chem. 277 (27) (2002) 24799-24808.
10. M.C. Byrns, L. Duan, S.H. Lee, I.A. Blair, T.M. Penning, Aldo-keto reductase 1C3 expression in MCF-7 cells reveals roles in steroid hormone and prostaglandin metabolism that may explain its over-expression in breast cancer, J. Steroid Biochem. Mol. Biol. 118 (3) (2010) 177-187.
11. T.M. Penning, M.C. Byrns, Steroid hormone transforming aldo-keto reductases and cancer, Ann. N.Y. Acad. Sci. 1155 (2009) 33-42.
12. H.J. Martin, E. Maser, Role of human aldo-keto-reductase AKR1B10 in the protection against toxic aldehydes, Chem. Biol. Interact. 178 (1-3) (2009) 145-150.
13. R. Ramasamy, I.J. Goldberg, Aldose reductase and cardiovascular diseases, creating human-like diabetic complications in an experimental model, Circ. Res. 106 (9) (2010) 1449-1458.
14. X. Pares, J. Farres, N. Kedishvili, G. Duester, Medium- and short-chain dehydrogenase/reductase gene and protein families: medium-chain and short-chain dehydrogenases/reductases in retinoid metabolism, Cell. Mol. Life Sci. 65 (24) (2008) 3936-3949.
15. B. Crosas, D.J. Hyndman, O. Gallego, S. Martras, X. Pares, T.G. Flynn, J. Farres, Human aldose reductase and human small intestine aldose reductase are efficient retinal reductases: consequences for retinoid metabolism, Biochem. J. 373 (Pt 3) (2003) 973-979. (Pubitemid 36981109)
16. S. Fukumoto, N. Yamauchi, H. Moriguchi, Y. Hippo, A. Watanabe, J. Shibahara, H. Taniguchi, S. Ishikawa, H. Ito, S. Yamamoto, H. Iwanari, M. Hironaka, Y. Ishikawa, T. Niki, Y. Sohara, T. Kodama, M. Nishimura, M. Fukayama, H. Dosaka-Akita, H. Aburatani, Overexpression of the aldo-keto reductase family protein AKR1B10 is highly correlated with smokers' non-small cell lung carcinomas, Clin. Cancer Res. 11 (5) (2005) 1776-1785.
17. S. Heringlake, M. Hofdmann, A. Fiebeler, M.P. Manns, W. Schmiegel, A. Tannapfel, Identification and expression analysis of the aldo-ketoreductase1-B10 gene in primary malignant liver tumours, J. Hepatol. 52 (2) (2010) 220-227.
18. H. Yoshitake, M. Takahashi, H. Ishikawa, M. Nojima, H. Iwanari, A. Watanabe, H. Aburatani, K. Yoshida, K. Ishi, K. Takamori, H. Ogawa, T. Hamakubo, T. Kodama, Y. Araki, Aldo-keto reductase family 1, member B10 in uterine carcinomas: a potential risk factor of recurrence after surgical therapy in cervical cancer, Int. J. Gynecol. Cancer 17 (6) (2007) 1300-1306. (Pubitemid 350077355)
19. R. Yan, X. Zu, J. Ma, Z. Liu, M. Adeyanju, D. Cao, Aldo-keto reductase family 1 B10 gene silencing results in growth inhibition of colorectal cancer cells: implication for cancer intervention, Int. J. Cancer 121 (10) (2007) 2301-2306. (Pubitemid 47585613)
20. J. Ma, R. Yan, X. Zu, J.M. Cheng, K. Rao, D.F. Liao, D. Cao, Aldo-keto reductase family 1 B10 affects fatty acid synthesis by regulating the stability of acetyl-CoA carboxylase-alpha in breast cancer cells, J. Biol. Chem. 283 (6) (2008) 3418-3423.
21. C. Naujokat, S. Hoffmann, Role and function of the 26S proteasome in proliferation and apoptosis, Lab. Invest. 82 (8) (2002) 965-980.
22. D.H. Wolf, W. Hilt, The proteasome: a proteolytic nanomachine of cell regulation and waste disposal, Biochim. Biophys. Acta 1695 (1-3) (2004) 19-31.
23. M. Muratani, W.P. Tansey,Howthe ubiquitin-proteasome system controls transcription, Nat. Rev. Mol. Cell Biol. 4 (3) (2003) 192-201. (Pubitemid 36288041)
24. A.M. Burger, A.K. Seth, The ubiquitin-mediated protein degradation pathway in cancer: therapeutic implications, Eur. J. Cancer 40 (15) (2004) 2217-2229. (Pubitemid 39348871)
25. J.C. Cusack Jr., R. Liu, M. Houston, K. Abendroth, P.J. Elliott, J. Adams, A.S. Baldwin Jr., Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition, Cancer Res. 61 (9) (2001) 3535-3540. (Pubitemid 32694955)
26. S.M. Russo, J.E. Tepper, A.S. Baldwin Jr., R. Liu, J. Adams, P. Elliott, J.C. Cusack Jr., Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB, Int. J. Radiat. Oncol. Biol. Phys. 50 (1) (2001) 183-193.
27. H.J. Lenz, Clinical update: proteasome inhibitors in solid tumors, Cancer Treat. Rev. 29 (Suppl. 1) (2003) 41-48.
28. Y.H. Ling, L. Liebes, Y. Zou, R. Perez-Soler, Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells, J. Biol. Chem. 278 (36) (2003) 33714-33723. (Pubitemid 37553204)
29. Z.X. Du, H.Y. Zhang, X. Meng, Y. Guan, H.Q. Wang, Role of oxidative stress and intracellular glutathione in the sensitivity to apoptosis induced by proteasome inhibitor in thyroid cancer cells, BMC Cancer 9 (2009) 56.
30. K. Itoh, N. Wakabayashi, Y. Katoh, T. Ishii, T. O'Connor, M. Yamamoto, Keap1 regulates both cytoplasmic-nuclear shuttling and degradation of Nrf2 in response to electrophiles, Genes Cells 8 (4) (2003) 379-391. (Pubitemid 36504013)
31. H. Dreger, K. Westphal, A. Weller, G. Baumann, V. Stangl, S. Meiners, K. Stangl, Nrf2-dependent upregulation of antioxidative enzymes: a novel path way for proteasome inhibitor-mediated cardioprotection, Cardiovasc. Res. 83 (2) (2009) 354-361.
32. J. Loeffler-Ragg, D. Mueller, G. Gamerith, T. Auer, S. Skvortsov, B. Sarg, I. Skvortsova, K.J. Schmitz, H.J. Martin, J. Krugmann, H. Alakus, E. Maser, J. Menzel, W. Hilbe, H. Lindner, K.W. Schmid, H. Zwierzina, Proteomic identification of aldo-keto reductase AKR1B10 induction after treatment of colorectal cancer cells with the proteasome inhibitor bortezomib, Mol. Cancer Ther. 8 (7) (2009) 1995-2006.
33. T.M. Penning, J.E. Drury, Human aldo-keto reductases: function, gene regulation, and single nucleotide polymorphisms, Arch. Biochem. Biophys. 464 (2) (2007) 241-250.
34. B. Ebert, M. Kisiela, P. Malatkova, Y. El-Hawari, E. Maser, Regulation of human carbonyl reductase 3 (CBR3; SDR21C2) expression by Nrf2 in cultured cancer cells, Biochemistry 49 (39) (2010) 8499-8511.
35. K.R. Stayrook, P.M. Rogers, R.S. Savkur, Y. Wang, C. Su, G. Varga, X. Bu, T. Wei, S. Nagpal, X.S. Liu, T.P. Burris, Regulation of human 3 alpha-hydroxysteroid dehydrogenase (AKR1C4) expression by the liver X receptor alpha, Mol. Pharmacol. 73 (2) (2008) 607-612.
36. M.E. Burczynski, R.G. Harvey, T.M. Penning, Expression and characterization of four recombinant human dihydrodiol dehydrogenase isoforms: oxidation of trans-7,8-dihydroxy-7,8-dihydrobenzo[a]pyrene to the activated o-quinone metabolite benzo[a]pyrene-7,8-dione, Biochemistry 37 (19) (1998) 6781-6790.
37. I.J. Hidalgo, T.J. Raub, R.T. Borchardt, Characterization of the human colon carcinoma cell line (Caco-2) as amodel system for intestinal epithelial permeability, Gastroenterology 96 (3) (1989) 736-749. (Pubitemid 19057595)
38. S. Homma, Y. Ishii, Y. Morishima, T. Yamadori, Y. Matsuno, N. Haraguchi, N. Kikuchi, H. Satoh, T. Sakamoto, N. Hizawa, K. Itoh, M. Yamamoto, Nrf2 enhances cell proliferation and resistance to anticancer drugs in human lung cancer, Clin. Cancer Res. 15 (10) (2009) 3423-3432.
39. H. Lou, S. Du, Q. Ji, A. Stolz, Induction of AKR1C2 by phase II inducers: identification of a distal consensus antioxidant response element regulated by NRF2, Mol. Pharmacol. 69 (5) (2006) 1662-1672.
40. H.G. Palmer, J.M. Gonzalez-Sancho, J. Espada, M.T. Berciano, I. Puig, J. Baulida, M. Quintanilla, A. Cano, A.G. de Herreros, M. Lafarga, A. Munoz, Vitamin D(3) promotes the differentiation of colon carcinoma cells by the induction of Ecadherin and the inhibition of beta-catenin signaling, J. Cell Biol. 154 (2) (2001) 369-387.
41. T. Murakami, M. Takano, Intestinal efflux transporters and drug absorption, Expert Opin. Drug Metab. Toxicol. 4 (7) (2008) 923-939.
42. S.V. Singh, S.K. Srivastava, S. Choi, K.L. Lew, J. Antosiewicz, D. Xiao, Y. Zeng, S.C. Watkins, C.S. Johnson, D.L. Trump, Y.J. Lee, H. Xiao, A. Herman-Antosiewicz, Sulforaphane-induced cell death in human prostate cancer cells is initiated by reactive oxygen species, J. Biol. Chem. 280 (20) (2005) 19911-19924.
43. U. Telang, D.A. Brazeau, M.E. Morris, Comparison of the effects of phenethyl isothiocyanate and sulforaphane on gene expression in breast cancer and normal mammary epithelial cells, Exp. Biol. Med. (Maywood) 234 (3) (2009) 287-295.
44. Y. Morel, N. Mermod, R. Barouki, An autoregulatory loop controlling CYP1A1 gene expression: role of H(2)O(2) and NFI, Mol. Cell. Biol. 19 (10) (1999) 6825-6832.
45. S.M. Deneke, B.A. Lynch, B.L. Fanburg, Transient depletion of lung glutathione by diethylmaleate enhances oxygen toxicity, J. Appl. Physiol. 58 (2) (1985) 571-574.
46. D.C. Kraft, C.C. Deocaris, R. Wadhwa, S.I. Rattan, Preincubation with the proteasome inhibitor MG-132 enhances proteasome activity via the Nrf2 transcription factor in aginghumanskin fibroblasts, Ann. N. Y. Acad. Sci. 1067 (2006) 420-424. (Pubitemid 43806354)
47. T. Pekol, J.S. Daniels, J. Labutti, I. Parsons, D. Nix, E. Baronas, F. Hsieh, L.S. Gan, G. Miwa, Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites, Drug Metab. Dispos. 33 (6) (2005) 771-777.